FDA Advisory Panel To Review New Heart Failure Drug From Novartis Forbes A novel acute heart failure drug from Novartis Novartis will be evaluated next month by an FDA advisory committee, perhaps countering a long string of crash-and-burn cardiology drugs. On February 13 the FDA's Cardiovascular and Renal Drugs Advisory ... |
